BMS ponders sales cuts due to Pargluva delay

Share this article:
Facing the reality that diabetes drug Pargluva (muraglitazar) won't be available for near-term promotion, Bristol-Myers Squibb is prepared to reduce its CV-metabolic sales force.
"The size of our current U.S. sales force was scaled to support a portfolio that we believed would be available for promotion," said Lamberto Andreotti, BMS executive vice president, president worldwide pharmaceuticals, during an investor meeting this week.
Pargluva was to be a centerpiece of that portfolio, but the FDA withheld approval in October, saying it needed more data from the company to examine the drug's risk for heart problems.
Cuts could come by early 2006, Andreotti said, if reps cannot be redistributed.
BMS has not stated whether it will pursue marketing approval for Pargluva. The product was not included among other compounds in a pipeline list provided for the investor meeting.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.